Hepatitis in 2010: the dawn of a new era in HCV therapy.

Nature reviews. Gastroenterology & hepatology ·Vol. 8 ·No. 2 ·2011-02-00 ·Pages 69-71

Ciesek S, Manns MP

Abstract

Although several antiviral treatments for HBV infection have recently reached the market, no direct acting antiviral drugs to treat infection with HCV have been licensed in the 20 years since its identification. Excitingly, recent publications herald several small revolutions in antiviral treatment of HCV that have considerable relevance for prospective HCV therapies.

MeSH Terms

Antiviral Agents/therapeutic use Drug Therapy, Combination Hepacivirus Hepatitis C, Chronic/drug therapy Humans Interferon alpha-2 Interferon-alpha/therapeutic use Oligopeptides/therapeutic use Polyethylene Glycols/therapeutic use Proline/analogs & derivatives,therapeutic use Recombinant Proteins Ribavirin/therapeutic use

Chemicals

Antiviral Agents Interferon alpha-2 Interferon-alpha Oligopeptides Recombinant Proteins Polyethylene Glycols Ribavirin telaprevir N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide Proline peginterferon alfa-2a

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Ciesek Sandra

Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Carl-Neuberg-Straβe 1, Hannover, Germany.

Manns Michael P

References (7)

7 references, click to expand

Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.
Gut. 2011 Jun;60(6):879 PMID: 20966029
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.
Science. 2005 Sep 2;309(5740):1577-81 PMID: 16141076
Telaprevir for previously treated chronic HCV infection.
N Engl J Med. 2010 Apr 8;362(14):1292-303 PMID: 20375406
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
Science. 2010 Jan 8;327(5962):198-201 PMID: 19965718
The way forward in HCV treatment--finding the right path.
Nat Rev Drug Discov. 2007 Dec;6(12):991-1000 PMID: 18049473
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Lancet. 2010 Aug 28;376(9742):705-16 PMID: 20692693
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Lancet. 2010 Oct 30;376(9751):1467-75 PMID: 20951424

Article Info

Journal

Nature reviews. Gastroenterology & hepatology

Abbr.

Nat Rev Gastroenterol Hepatol

ISSN

1759-5053

DOI

10.1038/nrgastro.2010.219

Published

2011-02-00

Pages

69-71

Language

English

Region

England

NLM ID

101500079

Subset

External Links

PubMed source DOI: 10.1038/nrgastro.2010.219 View journal details

Analysis Services

Hepatitis in 2010: the dawn of a new era in HCV therapy.

Contact

WeChat Official Account